Cargando…

Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model

Background: Previous studies have proven that Purinostat Mesylate (PM) is a new HDAC inhibitor and exhibits significant antitumor efficacy. However, the clinical application of PM was greatly limited by its poor solubility in water and low bioavailability. Objective:To increase the solubility of PM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Zejiang, Wen, Jiaolin, Xu, Yaohui, Pei, Heying, Li, Dan, Tang, Minghai, Bai, Peng, He, Jun, Yang, Zhuang, Chen, Lijuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903780/ https://www.ncbi.nlm.nih.gov/pubmed/35243950 http://dx.doi.org/10.1080/07853890.2022.2045347

Ejemplares similares

HDAC I/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cells
por: Qiu, Qiang, et al.
Publicado: (2022)

Antitumor Effects of Poplar Propolis on DLBCL SU-DHL-2 Cells
por: Liu, Xiaoqing, et al.
Publicado: (2023)

Data on cytotoxicity in HeLa and SU-DHL-4 cells exposed to DPB162-AE compound
por: Bittremieux, Mart, et al.
Publicado: (2017)

Validation of the diabetes, hypertension and hyperlipidemia (DHL) knowledge instrument in Malaysia
por: Lai, Pauline SM, et al.
Publicado: (2012)

Honokiol Ameliorates Post-Myocardial Infarction Heart Failure Through Ucp3-Mediated Reactive Oxygen Species Inhibition
por: Liu, Jianyu, et al.
Publicado: (2022)

Corrigendum: Honokiol ameliorates post-myocardial infarction heart failure through Ucp3-mediated reactive oxygen species inhibition
por: Liu, Jianyu, et al.
Publicado: (2022)

Extracellular vesicles from dHL-60 cells as delivery vehicles for diverse therapeutics
por: Kim, Jun-Kyu, et al.
Publicado: (2021)

Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo
por: Yang, Zhi-Ran, et al.
Publicado: (2020)

A size-shrinkable matrix metallopeptidase-2-sensitive delivery nanosystem improves the penetration of human programmed death-ligand 1 siRNA into lung-tumor spheroids
por: Wen, Jiaolin, et al.
Publicado: (2021)

ATP-dependent DNA helicase (TaDHL), a Novel Reduced-Height (Rht) Gene in Wheat
por: Guo, Baojin, et al.
Publicado: (2022)

The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications
por: Chen, Xi, et al.
Publicado: (2019)

Comportamiento de las enzimas CK, GOT y DHL en pacientes con infarto de miocardio
por: Alcolea Figueroa, María Elena
Publicado: (1987)

Manuka Honey Modulates the Inflammatory Behavior of a dHL-60 Neutrophil Model under the Cytotoxic Limit
por: Minden-Birkenmaier, Benjamin A., et al.
Publicado: (2019)

Formulation and characterization of novel soft nanovesicles for enhanced transdermal delivery of eprosartan mesylate
por: Ahad, Abdul, et al.
Publicado: (2017)

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy
por: Tremblay, Gabriel, et al.
Publicado: (2015)

The Effect of Manuka Honey on dHL-60 Cytokine, Chemokine, and Matrix-Degrading Enzyme Release under Inflammatory Conditions
por: Minden-Birkenmaier, Benjamin A., et al.
Publicado: (2019)

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
por: Gauden, Ruth, et al.
Publicado: (2011)

Injectable Gamboge-Based In Situ Gel for Sustained Delivery of Imatinib Mesylate
por: Jitrangsri, Kritamorn, et al.
Publicado: (2023)

Formulation and In Vitro, In Vivo Evaluation of Effervescent Floating Sustained-Release Imatinib Mesylate Tablet
por: Kadivar, Ali, et al.
Publicado: (2015)

Formulation and In-Vitro Characterization of Chitosan-Nanoparticles Loaded with the Iron Chelator Deferoxamine Mesylate (DFO)
por: Lazaridou, Maria, et al.
Publicado: (2020)

Formulation and characterization of eprosartan mesylate and β-cyclodextrin inclusion complex prepared by microwave technology
por: Ahad, Abdul, et al.
Publicado: (2022)

Validating the Digital Health Literacy Instrument in Relation to COVID-19 Information (COVID-DHL-K) among South Korean Undergraduates
por: Chun, Heeran, et al.
Publicado: (2022)

Índice DHL-neutrófilos-linfocitos como predictor de mortalidad a 28 días en pacientes con COVID-19
por: Rojas-Sahagún, Víctor Manuel, et al.
Publicado: (2023)

Cevipabulin-tubulin complex reveals a novel agent binding site on α-tubulin with tubulin degradation effect
por: Yang, Jianhong, et al.
Publicado: (2021)

Development and Validation of a Dissolution Test for Meloxicam and Pridinol Mesylate from Combined Tablet Formulation
por: Vignaduzzo, S. E., et al.
Publicado: (2010)

Spectrophotometric Determination of Gemifloxacin Mesylate, Moxifloxacin Hydrochloride, and Enrofloxacin in Pharmaceutical Formulations Using Acid Dyes
por: Gouda, Ayman A., et al.
Publicado: (2014)

Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patients
por: Mohajeri, Ehsan, et al.
Publicado: (2015)

Correction: Formulation and In Vitro, In Vivo Evaluation of Effervescent Floating Sustained-Release Imatinib Mesylate Tablet
Publicado: (2022)

Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate
por: Siti Mariam, Ismail, et al.
Publicado: (2022)

Effects of Tyrosine Kinase Inhibitor-masitinib Mesylate on Canine Mammary Tumour Cell Lines
por: Ustun-Alkan, Fulya, et al.
Publicado: (2021)

Development and Validation of a UV Spectrophotometric Method for the Simultaneous Estimation of Eprosartan Mesylate and Hydrochlorothiazide in Bulk and Formulations
por: Anandakumar, K., et al.
Publicado: (2011)

Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis
por: Pei, Heying, et al.
Publicado: (2018)

Establishment of a GIST-T1 gastrointestinal stromal tumour cell line resistant to imatinib mesylate
por: Zhou, Yongjian, et al.
Publicado: (2018)

The Survival Effect of Radiotherapy on Stage II/III Rectal Cancer in Different Age Groups: Formulating Radiotherapy Decision-Making Based on Age
por: Li, Yuqiang, et al.
Publicado: (2021)

Long‐term outcomes of relapsed/refractory double‐hit lymphoma (r/r DHL) treated with CD19/22 CAR T‐cell cocktail therapy
por: Wei, Jia, et al.
Publicado: (2020)

Synthesis, Characterization, and Pharmacodynamics Study of Enrofloxacin Mesylate
por: Pei, Lin-lin, et al.
Publicado: (2020)

Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)
por: Pinder, Elizabeth M., et al.
Publicado: (2007)

Preparation and evaluation of injectable Rasagiline mesylate dual-controlled drug delivery system for the treatment of Parkinson’s disease
por: Jiang, Ying, et al.
Publicado: (2017)

Periorbital edema secondary to imatinib mesylate
por: McClelland, Collin M, et al.
Publicado: (2010)

Cutaneous adverse effects of imatinib mesylate
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_q3kkb3e46ju5p07fbf35v9rr32